Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
You may also be interested in...
Of the nine specific appeal points raised against NICE’s rejection of the company’s antidepressant nasal spray, Spravato, just one was upheld.
The therapeutic indication of Spravato is set to be expanded in the EU after receiving the thumbs up from the European Medicines Agency. The nasal spray has been shown to reduce depressive symptoms in just four hours and would fill a key unmet need, says the drug’s developer, Janssen.
The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.